Stocks Health care CTMX
NASDAQ · Health careCytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. brought in $14M of revenue over the twelve months to September 30, 2026, down 87.7% from a year earlier. It posted a net loss of $85.4M. In fiscal 2025 capital spending exceeded operating cash flow by $75.8M. At September 30, 2026 it held $34M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about CytomX Therapeutics, Inc.
- Net worth
- CytomX Therapeutics, Inc. has a market value (market cap) of $431.4M at the latest share price, and shareholders' equity of $284.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $76.2M (-44.8% year on year), with a net loss of $17.4M. Over the 12 months to September 30, 2026: revenue $14M, net loss $85.4M.
- Cash flow
- In fiscal 2025 operations used $75.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- CytomX Therapeutics, Inc.'s next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What CytomX Therapeutics, Inc. does
CytomX Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTMX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $76.2M | -$17.4M | n/a | -$75.8M |
| 2024 | $138.1M | $31.9M | n/a | -$86.5M |
| 2023 | $101.2M | -$569K | n/a | -$56.9M |
| 2022 | $53.2M | -$99.3M | n/a | -$112.5M |
| 2021 | $37.3M | -$115.9M | n/a | -$120.6M |
| 2020 | $68.4M | -$64.8M | n/a | $3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CTMX ranks in Health care
Latest SEC filings
What CytomX Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 72% to $1.7M versus the same quarter last year; net loss of $20M.
- October 28, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 92% to $1.4M versus the same quarter last year; net loss of $20.7M.
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running CytomX Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 3, 2026 | Carvajal AlejandraChief Legal Officer | Received as pay | 100,000 | - |
| June 15, 2026 | Ogden ChristopherChief Financial Officer | Sold | 1,624 | $5K |
| March 17, 2026 | Ogden ChristopherChief Financial Officer | Sold | 19,323 | $124.1K |
| March 17, 2026 | Belvin MarciaSVP, Chief Scientific Officer | Sold | 31,492 | $202.3K |
| March 17, 2026 | McCarthy Sean A.CEO, Director | Soldpre-planned (10b5-1) | 118,969 | $764.1K |
| March 17, 2026 | Chu Yu-WayeChief Medical Officer | Sold | 21,279 | $136.7K |
| February 2, 2026 | McCarthy Sean A.CEO, Director | Received as pay | 210,000 | - |
| February 2, 2026 | Ogden ChristopherChief Financial Officer | Received as pay | 90,000 | - |
Who owns CTMX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.6% | February 5, 2026 |
| Kynam Capital Management, LP13G, passive with 2 related filers | 9.96% | August 14, 2026 |
| Patrick G. Enright13G, passive with 5 related filers | 7% | May 15, 2026 |
| Bank of America Corp13G, passive | 5.4% | October 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 179 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 32,714,937 | +759,300 |
| Kynam Capital Management, LP | 21,703,093 | +6,690,000 |
| BlackRock, Inc. | 17,559,822 | +12,331,542 |
| Bank of America Corp | 15,082,617 | +4,879,832 |
| State Street Corp | 11,747,236 | +6,083,828 |
| Perceptive Advisors LLC | 10,439,185 | +340,361 |
| Vanguard Capital Management LLC | 8,525,457 | -207,661 |
| Point72 Asset Management, L.P. | 7,811,033 | -64,357 |
| Wellington Management Group Llp | 5,168,961 | +1,585,976 |
| Venrock Adviser, LLC | 4,982,124 | -5,000,000 |
| Baker Bros. Advisors LP | 4,975,826 | 0 |
| Geode Capital Management, LLC | 4,678,716 | +2,612,104 |
| Elmind Capital, LP | 4,550,000 | 0 |
| Nextech Invest Ltd. | 4,449,932 | 0 |
| Two Sigma Investments, LP | 4,132,643 | +1,422,487 |
| Eversept Partners, LP | 3,558,497 | +369,983 |
| UBS Group AG | 3,468,359 | +348,204 |
| Siren, L.L.C. | 3,457,711 | 0 |
| ADAR1 Capital Management, LLC | 3,365,118 | -45,072 |
| Citadel Advisors LLC | 3,110,509 | -2,295,684 |
Insiders
6 insiders reported holding 1,984,452 shares in total, about $3.9M at the last price.
| Holder | Shares |
|---|---|
| McCarthy Sean A.CEO, Director | 1,078,922 |
| Belvin MarciaSVP, Chief Scientific Officer | 300,760 |
| Ogden ChristopherChief Financial Officer | 295,324 |
| Chu Yu-WayeChief Medical Officer | 189,446 |
| Carvajal AlejandraChief Legal Officer | 100,000 |
| Lester RachaelChief Business Officer | 20,000 |
Questions about CTMX
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CTMX. Its shares trade on NASDAQ under the ticker CTMX.
What is CytomX Therapeutics, Inc.'s net worth?
CytomX Therapeutics, Inc. has a market value (market cap) of $431.4M at the latest share price, and shareholders' equity of $284.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CytomX Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $85.4M on revenue of $14M.
How much revenue does CytomX Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 CytomX Therapeutics, Inc. reported revenue of $14M. That is 87.7% less than a year earlier.
When did CytomX Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is CytomX Therapeutics, Inc.'s next earnings report?
CytomX Therapeutics, Inc.'s next report is expected around March 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CTMX with
Follow CTMX
Get an email when CytomX Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CytomX Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.